Sanjivani Paranteral
- Market cap
- ₹ 193 Cr.
- P/E
- 28.7x
- P/B
- 3.95x
- 52-week range
- 126 – 244
- ROE
- 16%
- ROCE
- 19.3%
- Dividend yield
- 0%
- Debt / equity
- 0.3
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- BSE
About
Sanjivani Paranteral Limited is engaged in the business of manufacturing pharmaceutical products. The Company’s products include oral solids, small volume parenteral and sterile powder formula. Its product category includes antibiotic, anti-emetic, non-steroidal anti-inflammatory drugs (NSAID) and analgesic, antimalarial, calcium and vitamin, sedative, steroid, cardiovascular, anti-fibrinolytic, anti-coagulant, vasoconstrictor, inotropic agent, multivitamin, nutrition, diuretic, anti-hypertensive, and others. Its anti-biotic includes Netilmicin Sulfate, Amikacin Sulfate, and Gentamycin Sulfate. Its anti-emetic includes Ranitidine Hydrochloride, Metoclopramide, Ondansetron, and Promethazine. Its NSAID and analgesic include Acetaminophen Injection and Diclofenac Sodium Injection. Its calcium and vitamins include Methylcobalamin 500 mcg/ml and Nicotinic Acid 10 mg/ml. Its sedative includes Midazolam Hydrochloride, and Diazepam. Its diuretic includes Furosemide.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Sanjivani Paranteral against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)28.7 against a typical 34.3: cheaper than most peers (1st = cheapest).98th of 220
- Sales growth+8.8% against a typical +15.6% from a year earlier.118th of 197
- Profit growth+32.9% against a typical +18.9% from a year earlier.65th of 160
- Share price, 3 months+4.4% against a typical −0.5%.73rd of 200
- Size₹ 192.9 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).120th of 199
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 14 | 15 | 13 | 16 | 18 | 17 | 18 | 18 | 16 | 21 | 11 | 19 |
| Expenses | 12 | 13 | 11 | 14 | 15 | 15 | 16 | 15 | 13 | 17 | 10 | 16 |
| Operating Profit | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 2 | 4 | 1 | 3 |
| OPM % | 15.1% | 13.2% | 16.8% | 14.2% | 15.7% | 14.7% | 14.4% | 14.8% | 14.5% | 17.3% | 8.7% | 17.5% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 2 | 2 | 3 | 1 | 3 |
| Tax % | 14.1% | 13.2% | 33.5% | 24.6% | 21.3% | 24.3% | 17.3% | 24.8% | 25.1% | 24.9% | 25.6% | 25.2% |
| Net Profit | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 1 | 2 |
| EPS in Rs | 1.71 | 1.65 | 1.08 | 1.46 | 1.97 | 1.6 | 1.84 | 1.43 | 1.34 | 2.13 | 0.77 | 1.87 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- −6%
- 5 Years
- 21%
- 3 Years
- 16%
- TTM
- −7%
- 10 Years
- 9%
- 5 Years
- 37%
- 3 Years
- 15%
- TTM
- −8%
- 10 Years
- 26%
- 5 Years
- 45%
- 3 Years
- 32%
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 24%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Sanjivani Paranteral | ₹ 173.05 | ₹ 193 Cr. | 28.7x | 4x | 16% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Ashwin A. Khemka
- Executive Chairman of the Board, Managing Director
- Pritesh Jain
- Chief Financial Officer
- Ravikumar Bogam
- Chief Compliance Officer, Company Secretary
- Srivardhan Ashwani Khemka
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.